- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07630935
Breast Cancer Risk Assessment in Night Shift Workers - Implementation of a Personalized Consultation (NIGHT-SCAN)
This study evaluates adherence to a personalized prevention plan in female night shift workers at increased risk of breast cancer. Night shift work is associated with circadian disruption and increased cancer risk, as well as cardiovascular and reproductive health risks.
Participants attend an initial consultation including clinical assessment and development of a personalized prevention plan targeting modifiable risk factors such as alcohol consumption, physical activity, smoking, diet, and weight.
Follow-up is conducted remotely over 5 years to assess adherence to recommendations and screening. Participant satisfaction and adherence to additional consultations are also evaluated.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Breast cancer is the most common cancer among women, and prognosis depends on early detection. Night shift work is associated with circadian rhythm disruption and increased cancer risk.
This single-center interventional study evaluates adherence to a personalized prevention plan (PPP) developed during an initial consultation. This consultation includes a review of medical history, a lifestyle assessment, and a physical examination.
The PPP targets modifiable risk factors, including smoking, alcohol consumption, diet, physical activity, and weight.
Participants are followed for 5 years, with assessments at 1, 2, 3, and 5 years. Adherence is defined as the implementation of at least one recommendation or the completion of prescribed screening tests.
Secondary objectives include assessing satisfaction with and adherence to cardiology and fertility consultations when recommended.
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Amelia FAVIER, MD
- Telefonnummer: +33 +331.42.17.81.14
- E-Mail: amelia.favier@aphp.fr
Studienorte
-
-
-
Paris, Frankreich, 75013
- Pitié Salpêtrière hospital
-
Kontakt:
- Amelia FAVIER, MD
- Telefonnummer: +33 +33.1.42.17.81.11
- E-Mail: amelia.favier@aphp.fr
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Female participants aged 18 years or older
- Night shift workers at Pitié-Salpêtrière Hospital
- Attending consultation for breast cancer risk assessment PGRC
- Affiliated with a social security system
- No personal history of breast cancer
- Provided informed consent (non-opposition procedure according to French regulations)
Exclusion Criteria:
- Pregnant or breastfeeding women
- Individuals under legal protection or deprived of liberty
- Individuals without standard health insurance coverage
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Participants with Personalized Prevention Plan
Participants receive a tailored prevention plan following risk assessment
|
Personalized recommendations for night shift workers targeting modifiable risk factors, including lifestyle, diet, physical activity, smoking, alcohol consumption, and adherence to screening
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Adherence to Personalized Prevention Plan established during the initial risk assessment consultation
Zeitfenster: At 1, 2, 3 and 5 years.
|
Proportion of participants adhering to at least one recommendation of the Personalized Prevention Plan or completing prescribed screening.
Percentage of participants who lost weight when overweight had been identified during the initial consultation.
Percentage of participants with modified sporting activity according to the recommendations at the initial consultation.
Percentage of participants who had quit smoking.
Percentage of participants who modified their alcohol consumption when it was excessive at the initial consultation.
Percentage of participants who changed their diets when a dietary imbalance was observed during the initial consultation.
Percentage of women who underwent screening as recommended following the initial consultation.
|
At 1, 2, 3 and 5 years.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Overal patient satisfaction
Zeitfenster: At 1, 2, 3 and 5 years
|
Patient satisfaction regarding the PPP will be assessed 1 year following the intervention using the validated "Patient Satisfaction Questionnaire Short Form (PSQ-18)", based on a 5-point Likert scale ranging from "strongly disagree" to "strongly agree"
|
At 1, 2, 3 and 5 years
|
|
Participant satisfaction with the adapted consultation to night work
Zeitfenster: At 1, 2, 3 and 5 years.
|
Satisfaction rate of women with the consultation system adapted to night.
Patient satisfaction will be assessed using the validated "Patient Satisfaction Questionnaire Short Form (PSQ-18)", based on a 5-point Likert scale ranging from "strongly disagree" to "strongly agree".
|
At 1, 2, 3 and 5 years.
|
|
Screening adherence to a cardiovascular consultation recommendation
Zeitfenster: At 1, 2, 3 and 5 years.
|
Proportion of participants who had the consultation with a cardiologist when recommended
|
At 1, 2, 3 and 5 years.
|
|
Screening adherence to a fertility consultation consultation recommendation
Zeitfenster: At 1, 2, 3 and 5 years.
|
Proportion of participants who had the consultation with a cardiologist when recommended
|
At 1, 2, 3 and 5 years.
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Amelia FAVIER, MD, Assistance Publique - Hôpitaux de Paris
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- APHP260459
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Data are available upon reasonable request The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients.
Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.
IPD-Sharing-Zeitrahmen
IPD-Sharing-Zugriffskriterien
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ICF
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Diagnose von Brusttumoren
-
Xijing HospitalAktiv, nicht rekrutierendBrustkrebs | Brustkrebs (Triple Negative Breast Cancer (TNBC))China
-
Novartis PharmaceuticalsAbgeschlossenMetastasierter Brustkrebs (MBC) | Locally Advance Breast Cancer (LABC)Vereinigtes Königreich, Spanien
-
Shanghai Henlius BiotechNoch keine RekrutierungBrustkrebs (Triple Negative Breast Cancer (TNBC))China
-
BioNTech SESeventh Framework ProgrammeAbgeschlossenBrustkrebs (Triple Negative Breast Cancer (TNBC))Schweden, Deutschland
-
Filipa Lynce, MDAstraZeneca; Daiichi SankyoRekrutierungBrustkrebs | HER2-positiver Brustkrebs | Invasiver Brustkrebs | Entzündlicher Brustkrebs Stadium III | HER2 Low Breast AdenokarzinomVereinigte Staaten
-
John MascarenhasNational Cancer Institute (NCI); National Institutes of Health (NIH); Celgene... und andere MitarbeiterAbgeschlossenIDH2-Mutation | Accelerated/Blast-phase Myeloproliferative Neoplasm | Myelofibrose in der chronischen PhaseVereinigte Staaten, Kanada
-
Jessica Mezzanotte SharpeRekrutierungNicht-kleinzelligem Lungenkrebs | Klassisches Hodgkin-Lymphom | Plattenepithelkarzinom Mund | Melanom (Hautkrebs) | Brustkrebs (Triple Negative Breast Cancer (TNBC)) | Invasives Mammakarzinom | Nierenzellkarzinom (Nierenkrebs) | MSI-H/dMMR RektumkarzinomVereinigte Staaten
Klinische Studien zur Personalized Prevention Plan
-
Astrolab bioEPS COMFAMAAbgeschlossen
-
McMaster UniversityAbgeschlossenOsteopenie | Osteoporose, postmenopausalKanada
-
West Chester University of PennsylvaniaAbgeschlossenPrävention von Stimmstörungen bei LehramtsstudentenVereinigte Staaten
-
Medifast, Inc.AbgeschlossenFettleibigkeitVereinigte Staaten
-
Stanford UniversityNational Cancer Institute (NCI)AbgeschlossenVerwendung von E-ZigarettenVereinigte Staaten
-
Pelin Büyüksandıç ÖzşenRekrutierungHuman Values-Oriented Cyberbullying Prevention ProgramTürkei (türkiye)
-
University of the Balearic IslandsInstituto de Salud Carlos IIINoch keine Rekrutierung
-
University of ArizonaAbgeschlossen
-
Halic UniversityAbgeschlossenSportphysiotherapieTruthahn
-
Stanford UniversityTobacco Related Disease Research ProgramZurückgezogenVerhalten, Gesundheit | Verhalten, RauchenVereinigte Staaten